Cipla To Invest Rs 415 Crore In South African Arm To Improve Capital Structure

The pharmaceutical company reported a consolidated net profit of Rs 1,571 crore for the quarter ending in December. This exceeded the Bloomberg-tracked analysts’ consensus estimate of Rs 1,208 crore.

The company’s revenue rose by 7.1% year-on-year to Rs 7,073 crore. Additionally, the earnings before interest, taxes, depreciation, and amortisation increased by 13.8% to Rs 1,989 crore, with the margins expanding to 28.1% from 26.5%.

Shares of Cipla on Monday closed 1.32% lower at Rs 1,420.55 apiece on the NSE, compared to a 0.52% fall in the benchmark Nifty 50 index. The stock has fallen 0.93% in the last 12 months.

Out of 37 analysts tracking the company, 24 maintain a ‘buy’ rating on the stock, eight recommend ‘hold’ and five suggest ‘sell’, according to Bloomberg data. The average of 12-month analysts’ price target implies a potential upside of 16.2%.

Related Posts

  • Pharma
  • February 17, 2025
  • 68 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 66 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%